Legal Settlements Devour Cash Flow, Dulling Bayer’s Pipeline and Agri Wins

Bayer’s shares have taken a beating despite a string of positive operational developments, as the cost of resolving legacy litigation consumes cash at a pace that overshadows progress in the pharmaceutical pipeline and a strong agricultural performance. The stock closed Monday at €35.21, down 6.85% over the past seven days and 28.39% below the February high of €49.17. More than 600,000 shares changed hands.

A €2 Billion Hole in Cash Flow

The root of investor skepticism is laid bare in the first-quarter results. While revenue rose 4.1% on a currency-adjusted basis to €13.4 billion and adjusted earnings per share climbed 12.9% to €2.71, the free cash flow sank to negative €2.32 billion — deeper than the negative €1.53 billion recorded a year earlier. The culprit: net cash outflows of €2.0 billion to settle legal claims related to PCB and glyphosate, dwarfing the €66 million paid out in the same period last year. Net financial debt rose to €32.5 billion from the end of 2025.

For the full year, Bayer reaffirmed its guidance with revenue of €44.5?billion to €46.5?billion and EBITDA before special items of €9.4?billion to €9.9?billion. But the free cash flow forecast of minus €2.5?billion to minus €1.5?billion — which would have been positive by €2.0?billion to €3.0?billion without litigation payments — underscores the toxic drag from the legal portfolio.

Pipeline Progress on Nubeqa

Amid the financial gloom, the oncology pipeline delivered a clinical milestone. On May 30, Bayer announced that the ARACOG Phase II study for Nubeqa (darolutamide) met its primary endpoint, supporting the drug’s potential to expand its approved indications. Nubeqa is a key growth asset in the pharma division, designed to offset revenue losses from patent expiries of older blockbusters. No further details on trial size or secondary endpoints were disclosed.

Should investors sell immediately? Or is it worth buying Bayer?

The pharma division, however, remains mixed. Revenue held steady at €4.25?billion, with Nubeqa and Kerendia growing but Xarelto and Eylea losing ground to generics and patent erosion. Segment EBITDA slipped 7.5% to €1.24?billion.

Crop Science Provides a Bright Spot

The agriculture arm, Crop Science, delivered a robust first quarter. Revenue rose 6.8% on a currency-adjusted basis to €7.6?billion, while EBITDA before special items surged nearly 18% to €3.0?billion. Strong seed sales for soybeans and corn, together with production cost savings from efficiency programs, drove the improvement.

That operational strength did not cushion the stock, which fell 3.83% on Monday alone — making it one of the worst performers in the DAX while the index declined just 0.4%.

Technicals and Analyst Sentiment

The share price has slipped below its 50-day moving average of €38.66 and is hovering near the 200-day average of €35.66. The relative strength index stands at 44.1, indicating neutral momentum with a bearish bias. Annualized 30-day volatility of 36.17% reflects persistent nervousness.

Despite the sell-off, analysts remain largely constructive. Of 11 polled in May, nine rated the stock a “buy” and two a “hold,” with a consensus price target of €48.82 — 38.5% above the current share price. Jefferies is the most cautious, with a “hold” rating and a €40 target, while Barclays rates it “overweight” at €50 and DZ Bank recommends “buy” at €51. For 2026, consensus EPS stands at €4.35, up from €2.81 in the first quarter alone.

Bayer at a turning point? This analysis reveals what investors need to know now.

Digital Credentials and Upcoming Catalysts

Bayer was also recognized in a digital culture study conducted by Instinctif Partners, receiving four stars alongside Merck KGaA as a leader in the chemical and pharmaceutical sector. The company scored especially well in the categories of messaging, behavior, and transmission, while competitors such as Celesio and AbbVie Deutschland lagged.

Investors are now looking ahead to the second-quarter results due on August 4. The numbers will test whether the pipeline momentum and agri strength can offset the cash drain from legal settlements. A dividend of €0.11 per share is currently forecast for 2026, offering a yield of just 0.31% — a further sign that near-term returns depend entirely on share-price recovery.

Ad

Bayer Stock: New Analysis - 2 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | LEGAL | boerse | 69468776 |